PAVmed (PAVM)
(Delayed Data from NSDQ)
$0.91 USD
+0.07 (8.29%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.89 -0.02 (-2.20%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.91 USD
+0.07 (8.29%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.89 -0.02 (-2.20%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
Zacks News
Why PAVmed Inc. (PAVM) Dipped More Than Broader Market Today
by Zacks Equity Research
PAVmed Inc. (PAVM) closed at $2.07 in the latest trading session, marking a -1.43% move from the prior day.
New Strong Buy Stocks for March 27th
by Zacks Equity Research
RCL, PAVM, BANC, PRLB and IBP have been added to the Zacks Rank #1 (Strong Buy) List on March 27, 2023.
Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
PAVmed Inc. (PAVM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
PAVmed Inc. (PAVM) Upgraded to Buy: Here's Why
by Zacks Equity Research
PAVmed Inc. (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PAVmed Inc. (PAVM) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
PAVmed Inc. (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why PAVmed Inc. (PAVM) Looks Ripe for Bottom Fishing
by Zacks Equity Research
PAVmed Inc. (PAVM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Company News for Apr 22, 2020
by Zacks Equity Research
Companies In The News Are: SYF, VXRT, PAVM, WAFD